Impax settles lawsuit with Sanofi's Genzyme
Sept 4 (Reuters) - Generic drug company Impax Laboratories Inc said it agreed to settle a lawsuit with French drugmaker Sanofi SA regarding the production and sale of the generic versions of two kidney disease drugs.
According to the terms of the settlement, Sanofi unit Genzyme agreed to grant Impax a license to sell a generic version of Renvela tablets by March 16, 2014.
Genzyme also agreed to license Impax to sell generic Renagel by Sept. 16, 2014.
The two drugs had net sales of $392 million in the first half of 2012, Impax said in a statement.
Impax shares closed at $23.67 on Friday on the Nasdaq.
- Dallas Ebola patient vomited outside apartment on way to hospital |
- Islamic State committing 'staggering' crimes in Iraq: U.N. report
- Global stocks succumb to growth fears; ECB trillion euro question awaits
- Hong Kong warns democracy protesters of firm response |
- Israel's Netanyahu to Obama: Don't allow Iran deal that leaves it at nuclear threshold